Literature DB >> 33722285

Prevalence of scabies and impetigo in school-age children in Timor-Leste.

Joshua R Francis1,2, Susana Vaz Nery3, Alexander Matthews4, Brandon Le3, Salvador Amaral2, Paul Arkell2, Merita Monteiro5, Naomi Clarke3, Terlinda Barros6, Joaquim de Jesus Mendonça6, Sonia Maria Exposto Gusmão6, Leonia Maria Dos Reis Seixas6, João Henrique Araújo da Piedade6, Daniel Engelman7, Andrew C Steer7, Nicholas S S Fancourt1,2, Jennifer Yan1,2, John Kaldor3.   

Abstract

BACKGROUND: Scabies and impetigo are endemic in many tropical, low- and middle-income countries. Mass drug administration (MDA) with ivermectin has emerged as a control strategy for these conditions. In 2019, Timor-Leste Ministry of Health planned to implement MDA including ivermectin for the control of lymphatic filariasis, so we undertook a baseline assessment of scabies and impetigo to better understand local epidemiology and contribute to future surveys assessing the impact of MDA.
METHODS: A cross-sectional school survey was conducted in April-May 2019 at six primary schools in a semi-urban (Dili) and two rural (Ermera and Manufahi) settings. Children under 19 years of age present at school on survey days were eligible to participate, of whom we enrolled 1183. Trained health workers interviewed and examined 1043 participants to clinically diagnose scabies using the 2020 International Alliance for the Control of Scabies (IACS) diagnostic criteria, as well as impetigo. Prevalence was adjusted for age and sex. Mixed-effects logistic regression models were used to analyse odds of scabies and impetigo infection. All models accounted for clustering at the school level through the use of random effect terms. Population attributable risk of scabies as a cause of impetigo was also estimated.
RESULTS: The overall weighted prevalence of scabies was 30.6%. Children in rural Manufahi were more likely to have scabies than those in semi-urban Dili (53.6% vs 28.2%, adjusted odds ratio [AOR] 3.5). Most cases of scabies were mild (3 to 10 lesions), and lesions were usually distributed on more than one body region. Scabies prevalence was lower among 10 to 14 year olds compared to 5 to 9 year olds. Overall weighted prevalence of impetigo was 11.3%. Relative to Dili, children in rural Ermera and Manufahi were twice as likely to have impetigo. Impetigo was twice as common in children with scabies than in those without, corresponding to an attributable risk of scabies as a cause of impetigo of 22.7%.
CONCLUSIONS: Scabies and impetigo prevalence in Timor-Leste is among the highest reported globally, particularly in rural areas. Scabies infestation was strongly associated with impetigo. Comprehensive control strategies are urgently needed in Timor-Leste.

Entities:  

Keywords:  Children; Impetigo; Scabies; Timor-Leste

Year:  2021        PMID: 33722285      PMCID: PMC7962383          DOI: 10.1186/s13071-021-04645-1

Source DB:  PubMed          Journal:  Parasit Vectors        ISSN: 1756-3305            Impact factor:   3.876


  6 in total

Review 1.  Estimating the global burden of scabies: what else do we need?

Authors:  V Cox; L C Fuller; D Engelman; A Steer; R J Hay
Journal:  Br J Dermatol       Date:  2020-07-09       Impact factor: 9.302

2.  Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin.

Authors:  Gregor Lawrence; Judson Leafasia; John Sheridan; Susan Hills; Janet Wate; Christine Wate; Janet Montgomery; Nirmala Pandeya; David Purdie
Journal:  Bull World Health Organ       Date:  2005-01-21       Impact factor: 9.408

3.  A community-based validation of the International Alliance for the Control of Scabies Consensus Criteria by expert and non-expert examiners in Liberia.

Authors:  Stephen L Walker; Shelui Collinson; Joseph Timothy; Samuel K Zayzay; Karsor K Kollie; Neima Candy; Eglantine Lebas; Katherine Halliday; Rachel Pullan; Mosoka Fallah; Michael Marks
Journal:  PLoS Negl Trop Dis       Date:  2020-10-05

4.  Impact of an Ivermectin Mass Drug Administration on Scabies Prevalence in a Remote Australian Aboriginal Community.

Authors:  Thérèse M Kearns; Richard Speare; Allen C Cheng; James McCarthy; Jonathan R Carapetis; Deborah C Holt; Bart J Currie; Wendy Page; Jennifer Shield; Roslyn Gundjirryirr; Leanne Bundhala; Eddie Mulholland; Mark Chatfield; Ross M Andrews
Journal:  PLoS Negl Trop Dis       Date:  2015-10-30

5.  Scabies and impetigo in Timor-Leste: A school screening study in two districts.

Authors:  Laura M Korte; Asha C Bowen; Anthony D K Draper; Kim Davis; Annette Steel; Ines Teodora; Ivonia Mascarenhas; Benjamin Dingle; Joshua R Francis
Journal:  PLoS Negl Trop Dis       Date:  2018-05-31

6.  The Prevalence of Scabies and Impetigo in the Solomon Islands: A Population-Based Survey.

Authors:  Daniel S Mason; Michael Marks; Oliver Sokana; Anthony W Solomon; David C Mabey; Lucia Romani; John Kaldor; Andrew C Steer; Daniel Engelman
Journal:  PLoS Negl Trop Dis       Date:  2016-06-27
  6 in total
  3 in total

1.  The efficacy of sampling strategies for estimating scabies prevalence.

Authors:  Nefel Tellioglu; Rebecca H Chisholm; Jodie McVernon; Nicholas Geard; Patricia Therese Campbell
Journal:  PLoS Negl Trop Dis       Date:  2022-06-09

2.  Estimation of scabies prevalence using simplified criteria and mapping procedures in three Pacific and southeast Asian countries.

Authors:  Shu Ki Tsoi; Susanna J Lake; Li Jun Thean; Alexander Matthews; Oliver Sokana; Mike Kama; Salvador Amaral; Lucia Romani; Margot Whitfeld; Joshua R Francis; Susana Vaz Nery; Michael Marks; John M Kaldor; Andrew C Steer; Daniel Engelman
Journal:  BMC Public Health       Date:  2021-11-10       Impact factor: 3.295

3.  Community control strategies for scabies: A cluster randomised noninferiority trial.

Authors:  Myra Hardy; Josaia Samuela; Mike Kama; Meciusela Tuicakau; Lucia Romani; Margot J Whitfeld; Christopher L King; Gary J Weil; Tibor Schuster; Anneke C Grobler; Daniel Engelman; Leanne J Robinson; John M Kaldor; Andrew C Steer
Journal:  PLoS Med       Date:  2021-11-10       Impact factor: 11.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.